Ionis Pharmaceuticals SEC Filings

Ionis Pharmaceuticals, Inc. reported preliminary 2025 U.S. net product sales of $105 million for its drug TRYNGOLZA. These figures are unaudited, may be adjusted, and are being shared ahead of the company’s full financial results, which are planned for February 2026. The sales number gives an early view of TRYNGOLZA’s commercial performance in the U.S. market but does not represent the company’s complete 2025 financial picture.

Ionis Pharmaceuticals' EVP and Chief Human Resources Officer, Shannon L. Devers, reported a series of option exercises and share sales on January 7, 2026. Devers exercised several non-qualified stock options to acquire common stock at exercise prices of $32.60, $37.58, $52.87, and $56.78, then sold the resulting shares in market transactions. Blocks sold included 25,545 shares at a weighted average price of $85.36 and 9,264 shares at a weighted average price of $84.62, among other trades. After these transactions, Devers directly held 17,494 shares of Ionis common stock. The sales were made under a Rule 10b5-1 trading plan adopted on September 3, 2024.

Capital World Investors reports beneficial ownership of 17,961,299 shares of Ionis Pharmaceuticals, Inc. common stock, representing 11.1% of the class, based on 161,974,393 shares believed outstanding as of the event date. The firm has sole voting and dispositive power over all reported shares and no shared power. It certifies that the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Ionis.

An affiliate of the issuer has filed a notice under Rule 144 to sell 9,390 shares of common stock through broker Stifel Nicolaus & Company on the Nasdaq market, with an aggregate market value of $795,117. The filing notes that 161,974,393 shares of the issuer’s common stock were outstanding at the time of the notice.

The shares to be sold were acquired from the issuer through stock option exercises on three dates in 2022, 2023, and 2024, all paid in cash. The person filing the notice previously sold 16,777 shares on 11/25/2025 for gross proceeds of $1,342,160 and 3,162 shares on 09/03/2025 for gross proceeds of $192,882. By signing, the seller represents they are not aware of undisclosed material adverse information about the issuer.

Ionis Pharmaceuticals reported that partner GSK delivered positive results from two pivotal Phase 3 B-Well studies of bepirovirsen for chronic hepatitis B. The trials, which enrolled over 1,800 patients across 29 countries, met their primary endpoint and showed a statistically significant, clinically meaningful functional cure rate when bepirovirsen was added to standard of care versus standard of care alone, with an acceptable safety profile.

Chronic hepatitis B affects more than 250 million people worldwide and is a leading cause of liver cancer. If approved, bepirovirsen could become the first finite, six‑month therapeutic option and a backbone for future treatment strategies. Under its 2019 licensing agreement with GSK, Ionis is eligible to receive an additional $150 million in regulatory and sales milestone payments and tiered royalties of 10–12% on net sales of bepirovirsen.

Ionis Pharmaceuticals EVP Research Eric Swayze reported multiple stock option exercises and related share sales on 01/02/2026. He exercised options for 5,125 and 18,338 shares of common stock at an exercise price of $60.89 per share and sold the same numbers of shares at weighted average prices of $78.57 and $79.27, respectively, under a Rule 10b5-1 trading plan.

After these transactions, Swayze held 30,453 Ionis common shares directly and 256 shares indirectly through his son. He also received a new grant of non-qualified stock options for 19,350 shares at an exercise price of $79.67, vesting 25% on 01/02/2027 with the rest vesting in 36 monthly installments over three years, while his son received options for 150 shares on the same terms, reported as indirectly owned.

Ionis Pharmaceuticals executive Patrick R. O'Neil, EVP CLO & General Counsel, received a grant of 19,350 non-qualified stock options on 01/02/2026. Each option gives the right to buy one share of Ionis common stock at an exercise price of $79.67 under the company’s Amended and Restated 2011 Equity Incentive Plan.

None of the options were exercisable on the grant date. Instead, 25% of the shares subject to the option will vest and become exercisable on 01/02/2027. The remaining options will then vest and become exercisable in 36 equal monthly installments over the following three years, creating a four-year total vesting period tied to continued service.

Ionis Pharmaceuticals reported an equity award for its Chief Executive Officer, Brett P. Monia. On 01/02/2026, he received a grant of 85,410 non-qualified stock options under the company’s Amended and Restated 2011 Equity Incentive Plan, with an exercise price of $79.67 per share.

According to the vesting terms, the option was not exercisable on the grant date. 25% of the shares subject to the option will vest and become exercisable on 01/02/2027, and the remaining shares will vest in 36 equal monthly installments over the following three years, ending before the option’s 01/01/2036 expiration date.

Ionis Pharmaceuticals executive Holly B. Kordasiewicz, EVP and Chief Development Officer, received a new stock option award. On 01/02/2026 she was granted a non-qualified stock option to buy 9,100 shares of Ionis Pharmaceuticals common stock at an exercise price of $79.67 per share under the company’s Amended and Restated 2011 Equity Incentive Plan.

The option was not exercisable for any shares on the grant date. According to the vesting schedule, 25% of the shares will vest and become exercisable on 01/02/2027, and the remaining shares will vest and become exercisable in 36 equal monthly installments over the following three years.